[go: up one dir, main page]

BRPI0917819B8 - compostos derivados poliméricos de benzil carbonato, conjugado de droga, formulação farmacêutica, e, uso de um conjugado - Google Patents

compostos derivados poliméricos de benzil carbonato, conjugado de droga, formulação farmacêutica, e, uso de um conjugado

Info

Publication number
BRPI0917819B8
BRPI0917819B8 BRPI0917819A BRPI0917819A BRPI0917819B8 BR PI0917819 B8 BRPI0917819 B8 BR PI0917819B8 BR PI0917819 A BRPI0917819 A BR PI0917819A BR PI0917819 A BRPI0917819 A BR PI0917819A BR PI0917819 B8 BRPI0917819 B8 BR PI0917819B8
Authority
BR
Brazil
Prior art keywords
conjugate
pharmaceutical formulation
drug
derivative compounds
carbonate derivative
Prior art date
Application number
BRPI0917819A
Other languages
English (en)
Inventor
Ambroise Arounaguiry
Melnick Bennett
Quinn Catherine
Jiang Cong
Yang Guohan
Li Jie
r brown Larry
Saunders Paul
That Hai Ton
Original Assignee
Baxalta GmbH
Baxalta Inc
Baxter Healthcare Sa
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Inc, Baxter Healthcare Sa, Baxter Int filed Critical Baxalta GmbH
Publication of BRPI0917819A2 publication Critical patent/BRPI0917819A2/pt
Publication of BRPI0917819B1 publication Critical patent/BRPI0917819B1/pt
Publication of BRPI0917819B8 publication Critical patent/BRPI0917819B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyethers (AREA)
  • Polyesters Or Polycarbonates (AREA)

Abstract

composto, conjugado de droga, formulação farmacêutica, e, uso de um conjugado a presente invenção refere-se a derivados poliméricos, que podem ser conjugados a uma droga contendo amino para melhorar suas propriedades in vivo. o derivado polimérico pode subsequentemente ser liberado para produzir a droga em uma forma original. métodos de preparo e uso destes derivados poliméricos e conjugados de droga são descritos.
BRPI0917819A 2008-08-22 2009-08-21 compostos derivados poliméricos de benzil carbonato, conjugado de droga, formulação farmacêutica, e, uso de um conjugado BRPI0917819B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18975108P 2008-08-22 2008-08-22
US61/189751 2008-08-22
PCT/US2009/054595 WO2010022320A2 (en) 2008-08-22 2009-08-21 Polymeric benzyl carbonate-derivatives

Publications (3)

Publication Number Publication Date
BRPI0917819A2 BRPI0917819A2 (pt) 2015-11-24
BRPI0917819B1 BRPI0917819B1 (pt) 2020-11-10
BRPI0917819B8 true BRPI0917819B8 (pt) 2021-05-25

Family

ID=41531695

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917819A BRPI0917819B8 (pt) 2008-08-22 2009-08-21 compostos derivados poliméricos de benzil carbonato, conjugado de droga, formulação farmacêutica, e, uso de um conjugado

Country Status (12)

Country Link
US (2) US8653131B2 (pt)
EP (1) EP2328619B1 (pt)
JP (1) JP5731385B2 (pt)
KR (1) KR101660059B1 (pt)
AU (1) AU2009282747B2 (pt)
BR (1) BRPI0917819B8 (pt)
CA (1) CA2731184C (pt)
DK (1) DK2328619T3 (pt)
ES (1) ES2617868T3 (pt)
MX (1) MX2011001887A (pt)
NZ (1) NZ591045A (pt)
WO (1) WO2010022320A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US11319408B2 (en) 2017-03-30 2022-05-03 Nof Corporation Hydrophilic polymer derivative having self-immolative acetal linker and conjugate using same
JP7672652B2 (ja) 2019-07-30 2025-05-08 マツモトファインケミカル株式会社 ケイ素イソシアナト化合物含有組成物及びその製造方法

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3960871A (en) 1971-12-27 1976-06-01 Sharps Associates Esters of thienobenzopyrans and thiopyranobenzopyrans
US3991194A (en) 1971-12-27 1976-11-09 Sharps Associates Heterocyclic esters of benzopyranopyridines
US4042694A (en) 1972-12-04 1977-08-16 Sharps Associates Novel heterocyclic esters of benzopyranopyridines
US4081449A (en) 1973-04-05 1978-03-28 Abbott Laboratories Heterocyclic esters of alkylphenyl benzopyranopyridines
US4025630A (en) 1973-09-19 1977-05-24 Abbott Laboratories Anesthesia methods using benzopyrans and esters thereof as pre-anesthesia medication
US3972880A (en) 1974-03-05 1976-08-03 Sharps Associates Morpholine containing esters of thienobenzopyrans and thiopyranobenzopyrans
US4105776A (en) 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
CA1102337A (en) 1976-02-13 1981-06-02 Miguel A. Ondetti Proline derivatives and related compounds
AU509899B2 (en) 1976-02-13 1980-05-29 E.R. Squibb & Sons, Inc. Proline derivatives and related compounds
US4046889A (en) 1976-02-13 1977-09-06 E. R. Squibb & Sons, Inc. Azetidine-2-carboxylic acid derivatives
CA1103257A (en) 1976-02-13 1981-06-16 Miguel A. Ondetti Proline derivatives and related compounds
CA1103256A (en) 1976-02-13 1981-06-16 Miguel A. Ondetti Proline derivatives and related compounds
CA1103255A (en) 1976-02-13 1981-06-16 Miguel A. Ondetti Proline derivatives and related compounds
FR2352812A1 (fr) 1976-05-10 1977-12-23 Hoffmann La Roche Procede de fabrication de composes aliphatiques tertiaires optiquement actifs
MTP837B (en) 1977-11-07 1979-10-22 Hoffman La Roche And Co Aktien Derivatives 2 finino-imidazolidire
JPS57192323A (en) 1981-05-18 1982-11-26 Nisshin Flour Milling Co Ltd Isoprenyl ether derivative
US4439364A (en) * 1982-09-01 1984-03-27 E. I. Du Pont De Nemours & Company Process for preparing antihypertensive 1-substituted cyclic lactam-2-carboxylic acids and their derivatives
AU600992B2 (en) 1986-10-28 1990-08-30 Smith Kline & French Laboratories Limited Tetrahydroisoquinolin-2-yl derivatives of carboxylic acids
US4975438A (en) 1987-07-10 1990-12-04 Hoffmann-La Roche Inc. Pentadieneamide compounds which have useful activity of treating a disease characterized by an excess of platelet activating factor
US4927838A (en) 1987-07-10 1990-05-22 Hoffman-La Roche Inc. Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors
US4927826A (en) 1987-07-10 1990-05-22 Hoffman-La Roche Inc. Cycloproylpropenamides useful as platelet activing factor (PAF) antagonists
US4916145A (en) 1987-07-10 1990-04-10 Hoffmann-La Roche Inc. Substituted n-[(pyridyl)alkyl]aryl-carboxamide
US4786646A (en) 1987-07-10 1988-11-22 Hoffmann-La Roche Inc. Cyclopropylpropenamides
IL87019A (en) 1987-07-10 1993-07-08 Hoffmann La Roche Substituted alkene carboxamides and derivatives, their manufacture and pharmaceutical compositions containing them
US4788206A (en) 1987-07-10 1988-11-29 Hoffmann-La Roche Inc. Pentadieneamides
US5086052A (en) 1987-07-17 1992-02-04 Abbott Laboratories Substituted 1,4,5,6-tetrahydro-2H-pyridazin-3-one and -3-thione compounds having lipoxygenase inhibitory activity
US4970210A (en) 1987-07-17 1990-11-13 Abbott Laboratories Triazinone lipoxygenase compounds
DE3734751A1 (de) 1987-10-14 1989-05-03 Basf Ag Zwischenprodukte und verfahren fuer die herstellung von sexualpheromonen von miniermotten
DE3821540A1 (de) 1988-06-25 1989-12-28 Boehringer Mannheim Gmbh Neue sulfonamide, verfahren zu ihrer herstellung sowie solche sulfonamide enthaltende arzneimittel
SE8900685D0 (sv) 1989-02-28 1989-02-28 Astra Ab New compounds
DE3925256A1 (de) 1989-07-29 1991-01-31 Basf Ag Substituierte 3-oxypropionsaeure-tert.-butylester
US5204463A (en) 1989-08-10 1993-04-20 Glaxo Inc. Substituted methoxyphenyl-4,5 dihydro-3(2H)-pridazinones having cardiotonic and beta blocking activities
US5096904A (en) 1989-09-01 1992-03-17 Glaxo Inc. Pyridazinones having cardiotonic and beta blocking activities
US5053338A (en) 1989-09-01 1991-10-01 Glaxo Inc. Kinetic resolution of pyridazinones using lipase
JP2648584B2 (ja) 1990-02-16 1997-09-03 株式会社ディ・ディ・エス研究所 グリコシル−蛋白誘導体
JP2791001B2 (ja) 1990-02-16 1998-08-27 株式会社ディ・ディ・エス研究所 グリコシル−蛋白誘導体
JPH085914B2 (ja) 1990-02-16 1996-01-24 株式会社ディ・ディ・エス研究所 グリコシル−蛋白誘導体
JP2589435B2 (ja) 1991-09-17 1997-03-12 株式会社ディ・ディ・エス研究所 糖修飾ポリリジン誘導体
ATE174916T1 (de) 1992-03-18 1999-01-15 Takeda Chemical Industries Ltd Imidazopyridazine als antiasthmatika
CA2242579A1 (en) 1996-01-09 1997-07-17 Eli Lilly And Company Benzimidzolyl neuropeptide y receptor antagonists
GB9600344D0 (en) 1996-01-09 1996-03-13 Lilly Co Eli Benzimidzolyl neuropeptide y receptor antagonists
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
AU7274098A (en) 1997-04-30 1998-11-24 Eli Lilly And Company Antithrombotic agents
CA2287901A1 (en) 1997-04-30 1998-11-05 Jefferson Ray Mccowan Antithrombotic agents
US6284756B1 (en) 1998-04-30 2001-09-04 Eli Lilly And Company Antithrombotic agents
JP4211099B2 (ja) 1998-11-09 2009-01-21 三菱化学株式会社 透明導電性積層シートの製造方法
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
ES2256082T3 (es) 1999-12-22 2006-07-16 Nektar Therapeutics Al, Corporation Derivados de polimeros hidrosolubles con impedimento esterico.
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
JP2004532799A (ja) 2000-10-11 2004-10-28 エスペリオン セラピューティクス，インコーポレイテッド コレステロール管理および関連用途のためのスルフィド化合物およびジスルフィド化合物ならびにそれらを含む組成物
EP1235294A3 (en) 2001-02-22 2005-06-22 Fuji Photo Film Co., Ltd. Electrolyte composition, method for producing the same and non-aqueous electrolyte secondary cell
US20050020694A1 (en) 2001-10-11 2005-01-27 Dasseux Jean-Louis Henri Sulfide and disulfide compounds and compositions for cholesterol management and related uses
EP1534823A4 (en) 2002-07-12 2008-12-31 Biomarin Pharm Inc USE OF ISOCYANATE BINDING AGENTS FOR PRODUCING BIOPOLYMER-HYDRAULIC ACTIVE SUBSTANCE CONJUGATES
CN100363348C (zh) 2002-10-04 2008-01-23 千禧药品公司 治疗炎性疾病的前列腺素d2受体拮抗剂
US20090181966A1 (en) 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
AU2004204136B2 (en) 2003-01-06 2008-10-09 Nektar Therapeutics Thiol-selective water-soluble polmer derivatives
AU2004210711B2 (en) 2003-02-12 2010-07-08 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
BRPI0407882B1 (pt) * 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
US7332164B2 (en) * 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
PT1620118E (pt) 2003-04-08 2014-10-16 Yeda Res & Dev Fármacos peguilados de modo reversível
AU2003902860A0 (en) 2003-06-06 2003-06-26 Daicel Chemical Industries, Ltd Benzimidazole compounds
US7345190B2 (en) 2003-11-12 2008-03-18 Ssv Therapeutics, Inc. Carnitine conjugates as dual prodrugs and uses thereof
WO2005068418A1 (en) 2003-12-24 2005-07-28 Esperion Therapeutics, Inc. Sulfide and disulfide compounds and compositions for cholesterol management and related uses
TWI345568B (en) 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
CA2561564A1 (en) 2004-04-07 2005-10-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
FR2875805B1 (fr) 2004-09-27 2006-12-29 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
CN100381420C (zh) 2005-03-23 2008-04-16 于勇海 一种n-乙酰基半胱氨酸衍生物与应用
WO2006104883A1 (en) 2005-03-28 2006-10-05 Shell Internationale Research Maatschappij B.V. Formation of heteroatom containing derivatives of paraffins
US20090270655A1 (en) 2005-03-28 2009-10-29 Howard Lam-Ho Fong Conversion of Alkylhalides Into Alcohol Alkoxylates
JP2006327984A (ja) 2005-05-26 2006-12-07 Fujifilm Holdings Corp ヘテロ二官能性オリゴエチレングリコールの合成方法及びこれを用いたバイオセンサーの製造方法
BRPI0611872B8 (pt) 2005-06-16 2021-05-25 Nektar Therapeutics reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica
JP2009523748A (ja) 2006-01-18 2009-06-25 シエナ ビオテク ソシエタ ペル アチオニ α７ニコチン性アセチルコリン受容体の調節物質およびそれらの治療への使用
JP4975353B2 (ja) 2006-04-07 2012-07-11 ジェイカムアグリ株式会社 被覆粒状植物活性物質
CN101282899B (zh) 2006-07-27 2011-05-11 三菱电机株式会社 电梯装置
CN101534643A (zh) * 2006-09-15 2009-09-16 安佐制药股份有限公司 用于递送寡核苷酸的基于位阻酯的生物可降解连接体
CA2671676C (en) 2006-12-27 2014-04-22 Baxter Healthcare Sa Von willebrand factor-and factor viii-polymer conjugates having a releasable linkage
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
TWI408137B (zh) 2007-04-19 2013-09-11 Glaxo Group Ltd 經取代之二唑衍生物、其醫藥用途及醫藥組合物
WO2009011285A1 (ja) 2007-07-13 2009-01-22 Taisho Pharmaceutical Co., Ltd. ヘテロアリールベンゼン化合物
EP2259798B1 (en) 2008-03-05 2013-12-11 Baxter International Inc. Surface-modified particles and methods for targeted drug delivery
JP5222187B2 (ja) 2009-03-12 2013-06-26 株式会社クボタ 有孔ブロックおよび有孔ブロックを備えた集水設備の施工方法
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery

Also Published As

Publication number Publication date
WO2010022320A2 (en) 2010-02-25
JP2012500804A (ja) 2012-01-12
BRPI0917819B1 (pt) 2020-11-10
US20100048483A1 (en) 2010-02-25
KR20110055681A (ko) 2011-05-25
DK2328619T3 (en) 2017-03-13
BRPI0917819A2 (pt) 2015-11-24
US8962549B2 (en) 2015-02-24
EP2328619B1 (en) 2016-12-07
ES2617868T3 (es) 2017-06-20
AU2009282747B2 (en) 2015-04-02
KR101660059B1 (ko) 2016-09-26
NZ591045A (en) 2013-01-25
US20140128445A1 (en) 2014-05-08
MX2011001887A (es) 2011-04-04
CA2731184A1 (en) 2010-02-25
EP2328619A2 (en) 2011-06-08
AU2009282747A1 (en) 2010-02-25
WO2010022320A3 (en) 2010-08-19
JP5731385B2 (ja) 2015-06-10
CA2731184C (en) 2017-03-21
US8653131B2 (en) 2014-02-18

Similar Documents

Publication Publication Date Title
CY1125300T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν οξειδιο-υδροξειδιο του σιδηρου
CY1121860T1 (el) Συνθετικα ενδιαμεσα για την παρασκευη συζευγματων ολιγοσακχαριτη-πρωτεϊνης
BRPI0910746B8 (pt) agente de reticulação, conjugado de agente de ligação celular-fármaco, seu uso, composto e composição farmacêutica
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
IL244812A0 (en) 6-ethyl, 23-methyl-cholic acid, its conjugates with glycine and taurine and pharmaceutical preparations containing them
BRPI0916877A2 (pt) composição farmacêutica e administração da mesma
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
WO2009140423A3 (en) Targeted polymer bioconjugates
BR112012026801B8 (pt) conjugados de pirrolobenzodiazepina direcionados, composição farmacêutica, uso dos mesmos para tratamento de uma doença proliferativa ou autoimune e ligante de medicamento
BR112013007577A2 (pt) conjugado, composição farmacêutica, molécula de conjugação com amatoxina e método para a síntese de um conjugado
CL2007001648A1 (es) Compuesto derivado de leptomicina; conjugado que comprende agente de unión a células unido a uno o mas de dichos derivados; composiciones farmacéuticas que comprenden dicho derivado o conjugado; util en el tratamiento del cancer; proceso de preparacion de un compuesto o de un conjugado de un derivado de leptomicina.
WO2009133352A3 (en) Lipid composition
SV2009003335A (es) Formulaciones para el cancer
NI201200038A (es) Conjugados de niacina y ácidos grasos y sus usos
UY30319A1 (es) Formulaciones de inhibidores de dpp iv
BRPI0617294B8 (pt) composição farmacêutica em gel hidroalcóolico e uso de testosterona
BRPI0908596A2 (pt) formulação e composição farmacêutica de liberação prolongada
CL2010001422A1 (es) Uso de dronedarona para la preparacion de un medicamento util en la prevencion de la fibrilacion/aleteo auricular permanente
BR112012003283A8 (pt) sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
BRPI0916936A2 (pt) composições faramacêuticas e métodos para produzir baixas concentrações de impureza da mesmas.
EP2386553A4 (en) BENZIMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
BRPI0917502A2 (pt) composição farmacêtica, e, métodos para usar um ácido orgânico ou um antioxidante, para evitar a descoloração causada quando ácido tranemaxâmico e ácido ascórbico são incorporados em uma mesma composição, e para produzir uma preparação farmacêutica sólida para administração oral
ATE549016T1 (de) Pharmazeutische zusammensetzungen mit verbesserten auflöseprofilen für schwerlösliche wirkstoffe
BRPI0910570A2 (pt) uso de bioconjugados, e, formulações farmacêuticas
CY1119315T1 (el) Στερεες μορφες που περιεχουν μελοξικαμη με βελτιωμενη στοματικη γευση και η διαδικασια για τηn προετοιμασια τους

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BAXALTA GMBH (CH) , BAXALTA INCORPORATED (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/405 (2006.01), A61K 47/60 (2017.01), A61P

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/08/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: EXTINTA A PATENTE, NOS TERMOS DO ARTIGO 86, DA LPI, E ARTIGO 14 DA PORTARIA 52/2023, REFERENTE AO NAO RECOLHIMENTO DA 16A RETRIBUICAO ANUAL (VIDE PARECER).